Real-world Prescribing Patterns of Antifungal drugs in Patients with Aspergillosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Globally, the number of patients with aspergillosis is increasing, and the mortality rate remains high. This study aimed to investigate prescribing patterns of antifungal drugs for patients with aspergillosis in South Korea using real-world data. Methods: This retrospective cross-sectional study was performed using National Patient Sample (NPS) data collected by the Health Insurance Review and Assessment Service (HIRA) during 2011-2020. The use of antifungal drugs in patients with aspergillosis was investigated. Results: A total of 1374 patients were identified: 333 patients with invasive pulmonary aspergillosis (IPA) (24.2%), 436 patients with other PA (31.7%), 73 patients with other forms of aspergillosis (5.3%), and 532 patients with unspecified aspergillosis (38.7%). The odds of receiving an antifungal prescription were higher for IPA than for other PA (aOR, 0.233; p<0.001), and higher for hematologic malignancies than for respiratory disorders other than cancer or infections (aOR, 10.018; p<0.001). During each hospitalization period, 56.1% (97/173) and 6.4% (11/173) of IPA hospitalizations received voriconazole and itraconazole monotherapy, respectively, whereas 44.3% (27/61) and 27.9% (17/61) of other PA hospitalizations received itraconazole and voriconazole monotherapy, respectively. Among outpatients with IPA, 67.5% (85/126) and 26.2% (33/126) received voriconazole and itraconazole alone, respectively, whereas among outpatients with other PA, 86.1% (68/79) and 12.7% (10/79) received itraconazole and voriconazole alone, respectively, during the year. Conclusion: In Korea, voriconazole monotherapy was preferred in IPA inpatients, and itraconazole monotherapy was preferred in other PA inpatients. In the ambulatory care settings for IPA and other PA, itraconazole monotherapy was preferred.
Abstract
Background: Globally, the number of patients with aspergillosis is increasing, and the mortality rate remains high. This study aimed to investigate prescribing patterns of antifungal drugs for patients with aspergillosis in South Korea using real-world data. Methods: This retrospective cross-sectional study was performed using National Patient Sample (NPS) data collected by the Health Insurance Review and Assessment Service (HIRA) during 2011-2020. The use of antifungal drugs in patients with aspergillosis was investigated. Results: A total of 1374 patients were identified: 333 patients with invasive pulmonary aspergillosis (IPA) (24.2%), 436 patients with other PA (31.7%), 73 patients with other forms of aspergillosis (5.3%), and 532 patients with unspecified aspergillosis (38.7%). The odds of receiving an antifungal prescription were higher for IPA than for other PA (aOR, 0.233; p<0.001), and higher for hematologic malignancies than for respiratory disorders other than cancer or infections (aOR, 10.018; p<0.001). During each hospitalization period, 56.1% (97/173) and 6.4% (11/173) of IPA hospitalizations received voriconazole and itraconazole monotherapy, respectively, whereas 44.3% (27/61) and 27.9% (17/61) of other PA hospitalizations received itraconazole and voriconazole monotherapy, respectively. Among outpatients with IPA, 67.5% (85/126) and 26.2% (33/126) received voriconazole and itraconazole alone, respectively, whereas among outpatients with other PA, 86.1% (68/79) and 12.7% (10/79) received itraconazole and voriconazole alone, respectively, during the year. Conclusion: In Korea, voriconazole monotherapy was preferred in IPA inpatients, and itraconazole monotherapy was preferred in other PA inpatients. In the ambulatory care settings for IPA and other PA, itraconazole monotherapy was preferred.
참고문헌 (25)
- Latgé JP, "Aspergillus fumigatus and aspergillosis", Clin Microbiol Rev, 12(2), pp.310~350 (1999)
- Khan AAH, "Fungal pollution of indoor environments and its management", Saudi J Biol Sci, 19(4), pp.405~426 (2012)
- Seyedmousavi S, "Aspergillus and aspergilloses in wild and domestic animals : a global health concern with parallels to human disease", Med Mycol, 53(8), pp.765~797 (2015)
- Bongomin F, "Global and multinational prevalence of fungal diseases-estimate precision", J Fungi(Basel), 3(4), pp.57~ (2017)
- Patterson TF, "Practice guidelines for the diagnosis and management of aspergillosis : 2016update by the Infectious Diseases Society of America", Clin Infect Dis, 63(4), pp.e1~ (2016)
- Husain S, "Invasive Aspergillosis in solid-organ transplant recipients : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice", Clin Transplant, 33(9), pp.e13544~ (2019)
- Tudesq JJ, "Invasive pulmonary aspergillosis in nonimmunocompromised hosts", Semin Respir Crit Care Med, 40(4), pp.540~547 (2019)
- Jenks JD, "Treatment of aspergillosis", J Fungi(Basel), 4(3), pp.98~ (2018)
- Ullmann AJ, "Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline", Clin Microbiol Infect, 24(Suppl 1), pp.e1~38 (2018)
- Tutar N, "Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease", Multidiscip Respir Med, 8(1), pp.59~ (2013)
- Vallabhaneni S, "Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013 external icon", Open Forum Infect Dis, 4(1) (2017)
- "Annual report on health insurance statistics"[URL]
- Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples", Epidemiol Health, 36, pp.e2014008~ (2014)
- "Patient sample data guide"[URL]
- Denning DW, "Chronic pulmonary aspergillosis : rationale and clinical guidelines for diagnosis and management", Eur Respir J, 47(1), pp.45~68 (2016)
- "HIRA_Drug Price Master_Medicine Main Ingredient"[URL]
- Tarka P, "Epidemiology of pulmonary aspergillosis in hospitalized patients in Poland during 2009-2016", Adv Exp Med Biol, 1160, pp.73~80 (2019)
- Maitre T, "Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis", Eur Respir J, 58(2), pp.2003345~ (2021)
- "Status of hospitals by national region"[URL]
- Ledoux MP, "Invasive Pulmonary Aspergillosis", Semin Respir Crit Care Med, 41(1), pp.80~98 (2020)
- Herbrecht R, "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Engl J Med, 347(6), pp.408~415 (2002)
- Herbrecht R, "Application of the 2008definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis : a collaborative study of the Mycoses Study Group(MSG 05)and the European Organization for Research and Treatment of Cancer Infectious Diseases Group", Clin Infect Dis, 60(5), pp.713~720 (2015)
- Denning DW, "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis", Clin Infect Dis, 34(5), pp.563~571 (2002)
- Denning DW, "NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis", Am J Med, 97(2), pp.135~144 (1994)
- "Drug benefit list"[URL]